Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHQKN6)

Drug Name

CART-19 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Phase 2	[1]
Chronic lymphocytic leukaemia	2A82.0	Phase 2	[1]
Non-hodgkin lymphoma	2B33.5	Phase 2	[2]
B-cell chronic lymphocytic leukaemia	2A82.00	Phase 1	[1]
B-cell lymphoma	2A86	Phase 1	[3]
Diffuse large B-cell lymphoma	2A81	Phase 1	[1]
Follicular lymphoma	2A80	Phase 1	[1]
Haematopoietic/lymphoid cancer	2B33.5	Phase 1	[1]
leukaemia	2A60-2B33	Phase 1	[3]
Mantle cell lymphoma	2A85.5	Phase 1	[1]
Prolymphocytic leukaemia	2A82.1	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[5]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[6]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[7]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[8]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[9]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[10]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[11]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[12]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	CAR-T-Cell-Therapy	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
2	ClinicalTrials.gov (NCT02030834) Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
3	ClinicalTrials.gov (NCT01626495) Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma
4	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
5	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
9	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
10	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
11	Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
12	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
13	ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL